Related Experiment Videos
Identification of the primary gene defect at the cytochrome P450 CYP2D locus
A C Gough1, J S Miles, N K Spurr
1Imperial Cancer Research Fund, Clare Hall Laboratories, South Mimms, Potters Bar, UK.
Abstract:
The mammalian cytochrome P450-dependent monooxygenase system is involved in the metabolism of drugs and chemical carcinogens. The role of these enzymes in toxicological response is exemplified by an autosomal recessive polymorphism at the cytochrome P450 CYP2D6 debrisoquine hydroxylase locus which results in the severely compromised metabolism of at least 25 drugs, and which in some cases can lead to life-threatening side-effects. In addition, this polymorphism, which affects 8-10% of the caucasian population, has been associated with altered susceptibility to lung and bladder cancer. Here we report the identification of the primary mutation responsible for this metabolic defect and the development of a simple DNA-based genetic assay to allow both the identification of most individuals at risk of drug side-effects and clarification of the conflicting reports on the association of this polymorphism with cancer susceptibility.
Insights
A genetic mutation in cytochrome P450 (CYP2D6) causes poor drug metabolism, leading to severe side effects. This study identifies the mutation and develops a DNA test to identify individuals at risk for adverse drug reactions and cancer susceptibility.
Area of Science:
- Pharmacogenomics
- Molecular Toxicology
- Biochemistry
Background:
- The cytochrome P450 (CYP450) monooxygenase system is crucial for metabolizing drugs and carcinogens.
- A common autosomal recessive polymorphism in CYP2D6 leads to impaired metabolism of over 25 drugs, causing severe adverse effects.
- This CYP2D6 polymorphism is linked to increased susceptibility to lung and bladder cancers in Caucasian populations (8-10%).
Purpose of the Study:
- To identify the primary genetic mutation responsible for the CYP2D6 metabolic defect.
- To develop a DNA-based genetic assay for identifying individuals at risk.
- To clarify the association between CYP2D6 polymorphism and cancer susceptibility.
Main Methods:
- Genetic sequencing to pinpoint the causative mutation in CYP2D6.
- Development of a DNA-based assay for genotyping.
- Association studies correlating genotype with drug metabolism and cancer risk.
Main Results:
- Identification of the specific primary mutation underlying the CYP2D6 metabolic deficiency.
- Successful development of a simple DNA assay for identifying individuals with the polymorphism.
- The assay aids in predicting drug response and understanding cancer risk variations.
Conclusions:
- The identified mutation and developed DNA assay are vital tools for personalized medicine.
- This advancement allows for proactive identification of individuals at risk for adverse drug reactions.
- The findings contribute to resolving conflicting data on CYP2D6's role in cancer susceptibility.